** Shares of cell-based therapy company THMO.O rise 15.9%
to $9.40
** THMO is developing convalescent plasma and antibody
therapeutic approaches against COVID-19 in collaboration with
joint venture partner ImmuneCyte Life Sciences Inc urn:newsml:reuters.com:*:nPn4TGr9Pa
** ImmuneCyte has acquired intellectual property of four
antibody drug candidates to treat COVID-19 virus
** THMO and ImmuneCyte are using their combined technology
to identify antibodies from blood of individuals who have
recovered from the disease, which could then be used as a
potential treatment - THMO
** Including session's gain, shares up ~114% YTD
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))